- Home
- QNRX vs KTTA Comparison
QNRX vs KTTA Comparison
Compare QNRX & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- KTTA
- Stock Information
- Founded
- QNRX 2018
- KTTA 2020
- Country
- QNRX United States
- KTTA United States
- Employees
- QNRX N/A
- KTTA N/A
- Industry
- QNRX Medical/Dental Instruments
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- KTTA Health Care
- Exchange
- QNRX Nasdaq
- KTTA Nasdaq
- Market Cap
- QNRX 4.8M
- KTTA 5.7M
- IPO Year
- QNRX N/A
- KTTA 2021
- Fundamental
- Price
- QNRX $13.03
- KTTA $0.72
- Analyst Decision
- QNRX
- KTTA
- Analyst Count
- QNRX 0
- KTTA 0
- Target Price
- QNRX N/A
- KTTA N/A
- AVG Volume (30 Days)
- QNRX 833.5K
- KTTA 86.1K
- Earning Date
- QNRX 11-07-2025
- KTTA 11-12-2025
- Dividend Yield
- QNRX N/A
- KTTA N/A
- EPS Growth
- QNRX N/A
- KTTA N/A
- EPS
- QNRX N/A
- KTTA N/A
- Revenue
- QNRX N/A
- KTTA N/A
- Revenue This Year
- QNRX N/A
- KTTA N/A
- Revenue Next Year
- QNRX N/A
- KTTA N/A
- P/E Ratio
- QNRX N/A
- KTTA N/A
- Revenue Growth
- QNRX N/A
- KTTA N/A
- 52 Week Low
- QNRX $5.01
- KTTA $0.65
- 52 Week High
- QNRX $48.30
- KTTA $4.35
- Technical
- Relative Strength Index (RSI)
- QNRX 54.33
- KTTA 44.71
- Support Level
- QNRX $12.00
- KTTA $0.69
- Resistance Level
- QNRX $17.84
- KTTA $0.78
- Average True Range (ATR)
- QNRX 4.54
- KTTA 0.04
- MACD
- QNRX -0.02
- KTTA -0.00
- Stochastic Oscillator
- QNRX 16.87
- KTTA 18.87
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).